Marketing-authorisation holder · United States
Sun Pharm
32 medicines in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
1–25 of 32
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ABSORICA LD16mg | 20mg | 24mg | 28mg | 32mg | 8mg · Capsule | Isotretinoin | United States | Marketed | 2019 |
| AMIFOSTINE500mg/vial · Injectable | Amifostine | United States | Not marketed | 2008 |
| BROMSITE0.075% acid · Solution/drops | Bromfenac | United States | Marketed | 2016 |
| BYNFEZIA PEN7mg base/2.8ml (eq 2.5mg base/ml) · Solution | Octreotide | United States | Marketed | 2024 |
| CARBIDOPA, LEVODOPA AND ENTACAPONE12.5mg; 200mg; 50mg | 18.75mg; 200mg; 75mg | 25mg; 200mg; 100mg | 31.25mg; 200mg; 125mg | 37.5mg; 200mg; 150mg | 50mg; 200mg; 200mg · Tablet | Carbidopa, Entacapone, Levodopa | United States | Marketed | 2012 |
| CARIPRAZINE HYDROCHLORIDE1.5mg base | 3mg base | 4.5mg base | 6mg base · Capsule | Cariprazine | United States | Not marketed | 2022 |
| CEQUA0.09% · Solution | Ciclosporin | United States | Marketed | 2018 |
| CERINTA0.02mg; 0.1mg · Tablet | Ethinyl estradiol, Levonorgestrel | United States | Not marketed | 2019 |
| DECITABINE50mg/vial · Powder | Decitabine | United States | Not marketed | 2014 |
| DEFLAZACORT18mg | 30mg | 36mg | 6mg · Tablet | Deflazacort | United States | Marketed | 2024 |
| DESVENLAFAXINE100mg base | 50mg base · Tablet, extended release | Desvenlafaxine | United States | Not marketed | 2013 |
| DOCEFREZ20mg/vial | 80mg/vial · Injectable | Docetaxel | United States | Not marketed | 2011 |
| DRIZALMA SPRINKLE20mg base | 30mg base | 40mg base | 60mg base · Capsule, delayed rel pellets | Duloxetine | United States | Marketed | 2019 |
| DULOXETINE HYDROCHLORIDE120mg base | 20mg base | 30mg base | 40mg base | 60mg base | 80mg base | 90mg base · Capsule, delayed rel pellets | Duloxetine | United States | Marketed | 2013 |
| EZALLOR SPRINKLE10mg base | 20mg base | 40mg base | 5mg base · Capsule | Rosuvastatin | United States | Not marketed | 2018 |
| FOSPHENYTOIN SODIUM50mg phenytoin na/ml · Injectable | Fosphenytoin | United States | Marketed | 2007 |
| FYREMADEL250mcg/0.5ml · Injectable | Ganirelix | United States | Marketed | 2018 |
| INFUGEM1200mg base/120ml (eq 10mg base/ml) | 1300mg base/130ml (eq 10mg base/ml) | 1400mg base/140ml (eq 10mg base/ml) | 1500mg base/150ml (eq 10mg base/ml) | 1600mg base/160ml (eq 10mg base/ml) | 1700mg base/170ml (eq 10mg base/ml) | 1800mg base/180ml (eq 10mg base/ml) | 1900mg base/190ml (eq 10mg base/ml) | 2000mg base/200ml (eq 10mg base/ml) | 2200mg base/220ml (eq 10mg base/ml) · Solution | Gemcitabine | United States | Not marketed | 2018 |
| KEMEYA3mg; 0.03mg · Tablet | Drospirenone, Ethinyl estradiol | United States | Not marketed | 2019 |
| KYRA3mg; 0.02mg · Tablet | Drospirenone, Ethinyl estradiol | United States | Not marketed | 2019 |
| LORATADINE10mg | 5mg · Tablet, chewable | Loratadine | United States | Marketed | 2018 |
| MEMANTINE HYDROCHLORIDE10mg | 5mg · Tablet | Memantine | United States | Marketed | 2010 |
| METHOTREXATE SODIUM2.5MG BASE | 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Methotrexate | United States | Marketed | 1953 |
| ODOMZO200mg base · Capsule | Sonidegib | United States | Marketed | 2015 |
| OPCICON ONE-STEP1.5mg · Tablet | Levonorgestrel | United States | Marketed | 2014 |